Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study
Abstract Background Recent artificial tear preparations have provided 0.2% concentration of sodium hyaluronate. However, no published data exist on their potential superiority against 0.1% in alleviating dry-eye-disease symptoms in cataract extraction surgery. Methods A total of 180 patients that un...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-02-01
|
| Series: | Eye and Vision |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40662-019-0131-8 |
| _version_ | 1818389548135088128 |
|---|---|
| author | Panagiota Ntonti Eirini-Kanella Panagiotopoulou Georgios Karastatiras Nektarios Breyannis Sevasti Tsironi Georgios Labiris |
| author_facet | Panagiota Ntonti Eirini-Kanella Panagiotopoulou Georgios Karastatiras Nektarios Breyannis Sevasti Tsironi Georgios Labiris |
| author_sort | Panagiota Ntonti |
| collection | DOAJ |
| description | Abstract Background Recent artificial tear preparations have provided 0.2% concentration of sodium hyaluronate. However, no published data exist on their potential superiority against 0.1% in alleviating dry-eye-disease symptoms in cataract extraction surgery. Methods A total of 180 patients that underwent cataract extraction surgery were randomly divided into 2 groups according to their postoperative regime: Study group (SG) received fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks, and additionally 0.2% sodium hyaluronate provided in the COMOD® device quid for 6 weeks. Control group (CG) received fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks, and additionally 0.1% sodium hyaluronate provided in the COMOD® device quid for 6 weeks. The following indexes were evaluated at 3 postoperative checkpoints: 1) Surface discomfort index (SDI) which was derived by four direct 10-scale Likert-type questions that were addressed to the patient and pertained to: a) foreign body sensation (FBS), b) blinking discomfort (BD), c) stinging sensation (SS), d) tearing sensation (TS), 2) Tear break-up time (TBUT), 3) Schirmer’s test, 4) Central corneal thickness (CCT), and 4) Central Corneal Sensitivity (CCS). Results Both groups showed reduced CCS values at all postoperative examination points; however, SG participants had significantly better CCS (all p < 0.05). SG had better TBUT than CG at the 3rd (p = 0.03) and 6th examination points (p = 0.04). Moreover, SG had better SDI scores at the 3rd (SDI = 9.26 ± 0.55) and 6th weeks (SDI = 9.47 ± 0.48) vs. CG participants (p = 0.03 and p < 0.01, respectively). Conclusion The increased 0.2% sodium hyaluronate concentration in the artificial tears provided in the COMOD® device seems to address dry-eye-disease symptoms better in patients who underwent phacoemulsification surgery than the 0.1% concentration. Trial registration ClinicalTrials.gov Identifier: NCT03705949 Oct 15, 2018, retrospectively registered. |
| first_indexed | 2024-12-14T04:43:29Z |
| format | Article |
| id | doaj.art-dd406554849e4418b99bcd2c8a3f0a31 |
| institution | Directory Open Access Journal |
| issn | 2326-0254 |
| language | English |
| last_indexed | 2024-12-14T04:43:29Z |
| publishDate | 2019-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Eye and Vision |
| spelling | doaj.art-dd406554849e4418b99bcd2c8a3f0a312022-12-21T23:16:44ZengBMCEye and Vision2326-02542019-02-01611910.1186/s40662-019-0131-8Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative studyPanagiota Ntonti0Eirini-Kanella Panagiotopoulou1Georgios Karastatiras2Nektarios Breyannis3Sevasti Tsironi4Georgios Labiris5Department of Ophthalmology, University Hospital of AlexandroupolisDepartment of Ophthalmology, University Hospital of AlexandroupolisDepartment of Ophthalmology, Naval Hospital of AthensDepartment of Ophthalmology, Athinaiki KlinikiDepartment of Ophthalmology, Papanikolaou General HospitalDepartment of Ophthalmology, University Hospital of AlexandroupolisAbstract Background Recent artificial tear preparations have provided 0.2% concentration of sodium hyaluronate. However, no published data exist on their potential superiority against 0.1% in alleviating dry-eye-disease symptoms in cataract extraction surgery. Methods A total of 180 patients that underwent cataract extraction surgery were randomly divided into 2 groups according to their postoperative regime: Study group (SG) received fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks, and additionally 0.2% sodium hyaluronate provided in the COMOD® device quid for 6 weeks. Control group (CG) received fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks, and additionally 0.1% sodium hyaluronate provided in the COMOD® device quid for 6 weeks. The following indexes were evaluated at 3 postoperative checkpoints: 1) Surface discomfort index (SDI) which was derived by four direct 10-scale Likert-type questions that were addressed to the patient and pertained to: a) foreign body sensation (FBS), b) blinking discomfort (BD), c) stinging sensation (SS), d) tearing sensation (TS), 2) Tear break-up time (TBUT), 3) Schirmer’s test, 4) Central corneal thickness (CCT), and 4) Central Corneal Sensitivity (CCS). Results Both groups showed reduced CCS values at all postoperative examination points; however, SG participants had significantly better CCS (all p < 0.05). SG had better TBUT than CG at the 3rd (p = 0.03) and 6th examination points (p = 0.04). Moreover, SG had better SDI scores at the 3rd (SDI = 9.26 ± 0.55) and 6th weeks (SDI = 9.47 ± 0.48) vs. CG participants (p = 0.03 and p < 0.01, respectively). Conclusion The increased 0.2% sodium hyaluronate concentration in the artificial tears provided in the COMOD® device seems to address dry-eye-disease symptoms better in patients who underwent phacoemulsification surgery than the 0.1% concentration. Trial registration ClinicalTrials.gov Identifier: NCT03705949 Oct 15, 2018, retrospectively registered.http://link.springer.com/article/10.1186/s40662-019-0131-8CataractPostoperative regimeArtificial tearsSurface discomfort indexHylocomodHylogel |
| spellingShingle | Panagiota Ntonti Eirini-Kanella Panagiotopoulou Georgios Karastatiras Nektarios Breyannis Sevasti Tsironi Georgios Labiris Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study Eye and Vision Cataract Postoperative regime Artificial tears Surface discomfort index Hylocomod Hylogel |
| title | Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study |
| title_full | Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study |
| title_fullStr | Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study |
| title_full_unstemmed | Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study |
| title_short | Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study |
| title_sort | impact of 0 1 sodium hyaluronate and 0 2 sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery a comparative study |
| topic | Cataract Postoperative regime Artificial tears Surface discomfort index Hylocomod Hylogel |
| url | http://link.springer.com/article/10.1186/s40662-019-0131-8 |
| work_keys_str_mv | AT panagiotantonti impactof01sodiumhyaluronateand02sodiumhyaluronateartificialtearsonpostoperativediscomfortfollowingcataractextractionsurgeryacomparativestudy AT eirinikanellapanagiotopoulou impactof01sodiumhyaluronateand02sodiumhyaluronateartificialtearsonpostoperativediscomfortfollowingcataractextractionsurgeryacomparativestudy AT georgioskarastatiras impactof01sodiumhyaluronateand02sodiumhyaluronateartificialtearsonpostoperativediscomfortfollowingcataractextractionsurgeryacomparativestudy AT nektariosbreyannis impactof01sodiumhyaluronateand02sodiumhyaluronateartificialtearsonpostoperativediscomfortfollowingcataractextractionsurgeryacomparativestudy AT sevastitsironi impactof01sodiumhyaluronateand02sodiumhyaluronateartificialtearsonpostoperativediscomfortfollowingcataractextractionsurgeryacomparativestudy AT georgioslabiris impactof01sodiumhyaluronateand02sodiumhyaluronateartificialtearsonpostoperativediscomfortfollowingcataractextractionsurgeryacomparativestudy |